Speciality
Spotlight

       




 


Medicine


   

 




Nitric
Acid

   

  • Tim
    Higenbottam, Tom Siddons et al 
    (Divison of Clincial Sciences sheffield
    University, UK)

    Commentary
    – A therapeutic role for chronic inhaled nitric
    oxide.

    Lancet,
    Vol.356, August 5, 2000, pg. 446-447.

      

    Inhaled
    nitric oxide (NO) is a unique selective pulmonary
    vasodilator, which rapidly combines with oxy-haemoglobin
    to form methaemoglobin and nitrate in the alveolar
    capillaries. This
    combination ensures that the predominant effects are
    on the pulmonary vessels.

      

    Inhaled
    NO is a potential treatment for the many forms of
    pulmonary hypertension.
    Acutely inhaled NO at maximum doses is about
    half as effective a pulmonary vasodilator as IV
    prostacyclin. In
    hypoxic lung disease such as COPD, pulmonary
    hypertension increases risk of death.
    Inhaled NO is about twice as effective a
    pulmonary vasodilator as oxygen.

      

    Preliminary
    results from a randomized controlled study in
    Vienna, Austria, have shown that administration of
    spiked inhaled NO to patients with COPD on long-term
    oxygen therapy causes a sustained decrease in
    pulmonary artery pressure at 3 months without
    causing hypoxia. Results
    of long-term studies of inhaled NO in COPD are
    awaited.

        

 



 

           

Speciality Spotlight

       

 
Medicine
   

 

Nitric Acid
   

  • Tim Higenbottam, Tom Siddons et al  (Divison of Clincial Sciences sheffield University, UK)
    Commentary – A therapeutic role for chronic inhaled nitric oxide.
    Lancet, Vol.356, August 5, 2000, pg. 446-447.
      
    Inhaled nitric oxide (NO) is a unique selective pulmonary vasodilator, which rapidly combines with oxy-haemoglobin to form methaemoglobin and nitrate in the alveolar capillaries. This combination ensures that the predominant effects are on the pulmonary vessels.
      
    Inhaled NO is a potential treatment for the many forms of pulmonary hypertension. Acutely inhaled NO at maximum doses is about half as effective a pulmonary vasodilator as IV prostacyclin. In hypoxic lung disease such as COPD, pulmonary hypertension increases risk of death. Inhaled NO is about twice as effective a pulmonary vasodilator as oxygen.
      
    Preliminary results from a randomized controlled study in Vienna, Austria, have shown that administration of spiked inhaled NO to patients with COPD on long-term oxygen therapy causes a sustained decrease in pulmonary artery pressure at 3 months without causing hypoxia. Results of long-term studies of inhaled NO in COPD are awaited.
        

 

 

By |2022-07-20T16:41:59+00:00July 20, 2022|Uncategorized|Comments Off on Nitric Acid

About the Author: